- FDA approves five-day dosing regimen of Eisai's Dacogen for MDS
- FDA refuses to file NDA for Adventrx's investigational NSCLC treatment
- FDA grants ImmunoGen's investigational skin cancer compound orphan drug status
- FDA grants permission to Synta to resume testing of elesclomol in cancer
- Boxed warning added to Plavix label regarding possible reduced efficacy in certain patients
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Addition of radiotherapy to endocrine therapy has little negative long-term effect on QOL among men with prostate cancer, study shows
Friday, April 24 2009 | Comments
What's This?
The substantial benefits of adding radiotherapy to endocrine treatment for locally advanced prostate cancer outweigh significant increases in some treatment-related symptoms, research indicates, particularly since the symptoms often associated with radiotherapy appear to have little additional effect on quality of life (QOL) after 4 years.Researchers analyzed self-reported patient data from a previous open-label Phase III trial of 872 men with locally advanced prostate cancer who had received 3 months of total androgen blockade followed by either continuous endocrine treatment or the same endocrine treatment plus radiotherapy 3 months after study entry.
Disease-specific urinary, bowel, and sexual function symptoms, as well as QOL, were the primary outcome measures for this analysis.
Significantly more patients in the radiation group reported more moderate to severe urinary bother than in the endocrine-only group. Reports of bowel symptoms were also significantly higher in the radiation group.
Large proportions of both groups reported erectile dysfunction, although the condition was reported by significantly more patients in the combined group than in the endocrine-only group (85% vs 72%; P=.0002).
At 4 years, however, the only QOL measure that differed significantly between the groups was social function, which was decreased among the subjects receiving radiotherapy.
"The addition of radiotherapy to endocrine treatment led to significant worsening of some symptoms. Clinically significant differences in radiotherapy-induced symptoms between treatment groups were expected, but they were also small," the authors concluded. "Relative to the benefit on overall survival, death from prostate cancer, and delayed prostate-specific antigen relapse, the increase of symptoms with the addition of radiotherapy seems small and has little effect on quality of life 4 years after treatment." (Fransson P, et al. Lancet Oncol 2009;10:370-380.)
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- White blood cell count in presence of elevated ESR, CRP level predicts infection status in patients undergoing total hip arthroplasty, researchers report
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Careful discharge planning, follow-up vital for high-risk neonates facing hospital discharge, updated AAP guidelines state
- School-based nutrition, exercise intervention program may not maintain BMI decreases through 10 months in overweight students, data indicate
- Careful discharge planning, follow-up vital for high-risk neonates facing hospital discharge, updated AAP guidelines state
- Infliximab infusion may increase risk of ventricular arrhythmias in patients with RA, data suggest
- MTA Cooperative Group uses 8-year MTA follow-up data to assess long-term outcomes in children with ADHD
- Radiation therapy for prostate cancer raises bladder, rectal cancer risk, study indicates
